CAPR Company Profile and Key Details

Q: Who are the executives of CAPR?

Dr. Deborah D. Ascheim M.D.ConsultantCatherine Lee KelleherConsultantDr. Deborah D. AscheimConsultantMr. Xavier AvatChief Bus. OfficerDr. Frank Isaac Litvack FACC, M.D.Executive ChairmanDr. Linda Marbán Ph.D.Co-Founder, Pres, Chief Executive Officer & DirectorMr. Anthony J. Bergmann M.B.A.Chief Financial Officer & Corporation TreasurerMs. Karen G. KrasneyExecutive Vice President, Gen. Counsel & Sec.Dr. Eduardo MarbánCo-Founder & Chairman of Scientific Advisory BoardDr. Kristi A. H. Elliott Ph.D.Chief Science Officer

NASDAQ : CAPR

Capricor Therapeutics

$33.58

1.12+3.45%

At Close 4:00 PM

70.34

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Capricor Therapeutics, Inc. (CAPR) stock declined over -7.95%, trading at $30.91 on NASDAQ, down from the previous close of $33.58. The stock opened at $33.50, fluctuating between $30.85 and $33.59 in the recent session.

Stock Snapshot

33.58

Prev. Close

1.41B

Market Cap

30.85

Day Low

-13.68

P/E Ratio

-2.26

EPS (TTM)

-0.9

Cash Flow per Share

33.5

Open

45.72M

Number of Shares

33.59

Day High

87.9%

Free Float in %

0.74

Book Value

1.74M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Apr 30, 2026	33.06	34.64	32.74	33.58	835.26K
Apr 29, 2026	33.91	34.11	32.28	32.46	770.87K
Apr 28, 2026	35.00	35.85	33.62	33.98	744.37K
Apr 27, 2026	35.31	35.46	34.12	35.10	993.06K
Apr 23, 2026	35.00	35.07	32.86	33.86	842.7K
Apr 22, 2026	35.77	35.99	34.53	35.00	590.78K
Apr 21, 2026	34.37	35.47	33.76	35.34	803.56K
Apr 20, 2026	34.87	36.82	33.90	34.21	1.04M
Apr 17, 2026	35.36	35.66	34.35	34.70	740.04K
Apr 16, 2026	35.29	35.45	33.44	34.59	848.95K
Apr 14, 2026	34.00	34.77	33.32	34.72	949.15K
Apr 13, 2026	31.21	35.99	30.90	34.54	2.29M
Apr 10, 2026	31.54	31.68	29.58	31.20	743.06K
Apr 09, 2026	31.22	32.13	30.98	31.61	685.8K
Apr 08, 2026	32.87	33.00	31.29	31.60	639.86K
Apr 07, 2026	31.37	31.98	30.33	31.97	709.98K
Apr 06, 2026	31.98	33.15	31.39	31.68	845.15K
Apr 02, 2026	29.09	32.40	28.91	32.11	1.22M
Apr 01, 2026	30.45	31.74	29.95	30.12	1.78M
Mar 31, 2026	28.53	30.49	28.30	30.40	1.94M

Contact Details

San Diego, CA 92121

United States

https://www.capricor.com 310 358 3200

About Company

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.

Stock Peers

ARGX

5.7+0.73%

argenx SE$781.72 REGN

20.7+3.02%

Regeneron Pharmaceuticals, Inc.$707.06 UTHR

0.28+0.05%

United Therapeutics Corporation$571.35 MDGL

-1.19-0.23%

Madrigal Pharmaceuticals, Inc.$517.39 VRTX

4.14+0.98%

Vertex Pharmaceuticals Incorporated$427.38 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

-4.36-1.35%

Praxis Precision Medicines, Inc.$318.83 ALNY

8.3+2.76%

Alnylam Pharmaceuticals, Inc.$309.49 KRYS

2.31+0.89%

Krystal Biotech, Inc.$262.26 LGND

4.59+2.04%

Ligand Pharmaceuticals Incorporated$229.45

Company Overview

Capricor Therapeutics, Inc. (NASDAQ:CAPR) closed at $30.91 USD, losing -$2.67 (-7.95%) from the previous close of $33.58. The stock is currently mid-range between its 52-week high and low $4.30 and $40.37. With a market capitalization of about $1.41 billion, Capricor Therapeutics, Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~0.48). Key stats such as the average daily volume over the past year has been around 1.26 million shares, in line with its 52-week average. Headquartered in San Diego, CA, Capricor Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Linda Marbán, the company employs approximately 160 people and listed since February 13, 2007. Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders.

Technical Performance

Short-term trend indicators are mixed aligned (SMA20 10.87%, SMA50 8.65%, SMA200 113.05%). The stock’s 14-day RSI is 59.98 (neutral), while the ATR of 1.68 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -30.91% below its high and over 548.6% above its low. Average 10-day trading volume of 796.18 thousand shares is below the 3-month average of 1.26 million, indicating normal recent market interest.

Valuation Metrics

Capricor Therapeutics, Inc. trades at a P/E ratio of -15.88, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 5.45 trading at moderately above to book value. The P/FCF stands at -19.14, also below market averages.

Dividend & Fair Value

Capricor Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $5.74. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Capricor Therapeutics, Inc. generated EPS of -$1.80 over the past year. Five-year average earnings growth is 11.01%. The latest quarter delivered EPS of -$0.62. The next quarter is forecast at -$0.51. Next year's EPS is expected at -$2.81. Analyst sentiment is bullish. Analyst rating data shows there are 4 Strong Buy ratings, 16 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $77.00 to $12.00. The high target offers 129.3% upside. The low target suggests -64.26% downside. The mean target is $42.70. This offers 27.16% upside. Capricor Therapeutics, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended March 12, 2026, missed forecasts by 21.57%. The prior quarter beat by 0.0%. Over the last six quarters, Apple has recorded several small beats. These include 11.76% in November 13, 2024.

Shareholding & Insider Activity

Capricor Therapeutics, Inc. has 45.72 million shares outstanding. The public float is 40.19 million shares, elevated short interest at 28.25% of float. This equals 11.35 million shares. The short ratio is 5.87 days. Institutional investors hold 36.69% of the float. Insiders own 16.79%. Nippon Shinyaku Co Ltd holds 7.09 million shares, CEDARS SINAI MEDICAL CENTER has 4.05 million shares and TANEN DAVID M has 1.52 million shares. Over the past six months, insider transactions show net selling. They sold 172.53 thousand shares across 5 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Capricor Therapeutics generated $25.18M in revenue, or $0.94 per share. Gross margin was 95.75%, operating margin -95.63%, and net profit margin -88.52%. Returns are negative, with ROA at -37.95% and ROE at -98.61%.
On valuation metrics, Capricor Therapeutics trades at a P/E of -15.88, P/S of 0.00 and P/B of 5.45. The current ratio is 9.01 and quick ratio is 9.01. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -9.85 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.07, supported by a cash flow-to-debt ratio of -3.33.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Capricor Therapeutics posted revenue of $25.18M, down slightly from $2.55M in the prior quarter. Gross profit was $24.11M (margin 95.75%). Operating income was - $24.08M (margin -95.6%). Net income was- $22.29M (EPS - $0.83).
The company ended the quarter with $39.49M in cash and short-term investments, a total debt of $5.61M, and net debt of - $9.08M. Total assets were $58.73M, with equity of $22.60M. Financials further reflected weakness, with operating cash flow of - $25.60M, free cash flow of - $27.64M, and capital expenditures of - $2.05M.

Price Forecast & Outlook

Our AI price prediction model suggests that Capricor Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 6.76%, with price expected at $35.85 by May 14, 2026, within a range of $34.56 to $37.33 3-Month Outlook: Projected fall of -32.34%, reaching $22.72 by July 29, 2026, with a range of $21.79 to $23.81. 1-Year Outlook: Projected gain of 20.16%, with price at $40.35 by April 30, 2027, within a range of $37.72 to $42.23.

Key Takeaways

Capricor Therapeutics, Inc. (NASDAQ:CAPR) shares are down -16.15% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Capricor Therapeutics, Inc. trading at a premium to the broader market with a P/E of -15.88. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $36.82, suggesting 9.65% upside. Our AI forecast model points to short-term strength (6.76% over two weeks), a medium-term fall (-32.34% over three months), and a longer-term gain (20.16% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Capricor Therapeutics, Inc. (CAPR) stock price?

Capricor Therapeutics, Inc. (NASDAQ: CAPR) stock price is $30.91 in the last trading session. During the trading session, CAPR stock reached the peak price of $33.59 while $30.85 was the lowest point it dropped to. The percentage change in CAPR stock occurred in the recent session was -7.95% while the dollar amount for the price change in CAPR stock was - $2.67.

CAPR's industry and sector of operation?

The NASDAQ listed CAPR is part of Biotechnology industry that operates in the broader Healthcare sector. Capricor Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of CAPR?

Dr. Deborah D. Ascheim M.D.
Consultant
Catherine Lee Kelleher
Consultant
Dr. Deborah D. Ascheim
Consultant
Mr. Xavier Avat
Chief Bus. Officer
Dr. Frank Isaac Litvack FACC, M.D.
Executive Chairman
Dr. Linda Marbán Ph.D.
Co-Founder, Pres, Chief Executive Officer & Director
Mr. Anthony J. Bergmann M.B.A.
Chief Financial Officer & Corporation Treasurer
Ms. Karen G. Krasney
Executive Vice President, Gen. Counsel & Sec.
Dr. Eduardo Marbán
Co-Founder & Chairman of Scientific Advisory Board
Dr. Kristi A. H. Elliott Ph.D.
Chief Science Officer

How CAPR did perform over past 52-week?

CAPR's closing price is 680.93% higher than its 52-week low of $4.30 where as its distance from 52-week high of $40.37 is -16.82%.

How many employees does CAPR have?

Number of CAPR employees currently stands at 160.

Link for CAPR official website?

Official Website of CAPR is: https://www.capricor.com

How do I contact CAPR?

CAPR could be contacted at phone 310 358 3200 and can also be accessed through its website. CAPR operates from 10865 Road to the Cure, San Diego, CA 92121, United States.

How many shares of CAPR are traded daily?

CAPR stock volume for the day was 1.74M shares. The average number of CAPR shares traded daily for last 3 months was 1.26M.

What is the market cap of CAPR currently?

The market value of CAPR currently stands at $1.41B with its latest stock price at $30.91 and 45.72M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	160
Beta	0.48
Sales or Revenue	$25.18M
5Y Sales Change%	0.653%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

CAPR Company Profile and Key Details

Capricor Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Company Overview

Dividend & Fair Value

Shareholding & Insider Activity

Earnings & Analyst Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Valuation Metrics